학술논문
Intestinal occlusion by gynecological cancers treated by percutaneous endoscopic gastrostomy and lanreotide: an Aviano National Cancer Institute experience
Commentary
Commentary
Document Type
Academic Journal
Author
Source
Supportive Care in Cancer. February 2021, Vol. 29 Issue 2, p547, 3 p.
Subject
Language
English
ISSN
0941-4355
Abstract
Author(s): Martina Budel [sup.1], Luca Martella [sup.2], Laura Zambon [sup.1], Isabella Morson [sup.1], Giorgio Giorda [sup.2], Renato Cannizzaro [sup.1] [sup.3] Author Affiliations: (1) grid.418321.d, 0000 0004 1757 9741, Oncological Gastroenterology, [...]
The Commentary reports on our experience in Centro di Riferimento Oncologico IRCCS Aviano about the integrated and combined treatment with percutaneous endoscopic gastrostomy and lanreotide in patients with bowel obstructions by ovarian cancer and peritoneal carcinomatosis. We treated patients with gynecological cancers and bowel obstruction with percutaneous endoscopic gastrostomy and, when patients were partially responsive, with lanreotide. We registered a constant overall benefit for the quality of life and for the control of symptoms, which is very important especially during the home care follow-up of terminal patients.
The Commentary reports on our experience in Centro di Riferimento Oncologico IRCCS Aviano about the integrated and combined treatment with percutaneous endoscopic gastrostomy and lanreotide in patients with bowel obstructions by ovarian cancer and peritoneal carcinomatosis. We treated patients with gynecological cancers and bowel obstruction with percutaneous endoscopic gastrostomy and, when patients were partially responsive, with lanreotide. We registered a constant overall benefit for the quality of life and for the control of symptoms, which is very important especially during the home care follow-up of terminal patients.